Heart Failure
Dapagliflozin improves stroke volume in patients with HFrEF
Reduction in atrial arrhythmias in patients with CIED on SGLT2 inhibitors
AHA: Biomarker highly predictive of dapagliflozin response in HFrEF
AI-powered, ECG-enabled stethoscope detects heart failure in primary care
Empagliflozin efficacious in HF patients with preserved ejection fractions ≥50%
EMPULSE: Empagliflozin improves outcomes of acute heart failure
CHIEF-HF: Canagliflozin improves health status in heart failure
DREAM-HF: MPC therapy for HFrEF did not meet primary endpoint
Therapeutic approaches in heart failure with diabetes
Bedside ultrasound detects central venous congestion in patients with heart failure
Dapagliflozin tied to reduction in new-onset diabetes in patients with CKD, heart failure
After a heart attack, sacubitril-valsartan no better than ramipril for heart-failure prevention
Novel index likely predicts outcomes in heart failure with severe secondary mitral regurgitation
Valsartan seems to attenuate hypertrophic cardiomyopathy progression
Dapagliflozin reduces incidence of sudden death in HFrEF patients
Empagliflozin: First drug with clear benefit in HFpEF patients
CardioMEMS: neutral outcome but possible benefit prior to COVID-19
Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD
2021 ESC Guidelines on Heart Failure
Adherence to sacubitril/valsartan for heart failure tied to risk of readmission, death
Remote heart-failure care tied to less diagnostic testing, less guideline-directed therapy
Empagliflozin benefits tied to drop in NT-proBNP levels in heart-failure patients
Monitoring PA pressure likely curbs heart-failure hospitalization in obese
ESC 2021 Highlights Podcast
Health status, exercise capacity help predict outcomes in heart failure with mitral regurgitation
Drug prevents some heart-failure hospitalizations when ejection fraction is preserved
Colchicine likely curbs MACE risk regardless of history, timing of prior acute coronary syndrome
REFILE-Progressive rehabilitation improves outcomes for elderly heart failure patients
Delaying diabetes onset a target for heart-failure prevention
Iron substitution improves LVEF in intensively treated CRT patients with iron deficiency
Novel mineralocorticoid receptor antagonist effective irrespective of HF history
Iron substitution in iron-deficient HF patients is highly cost-effective
Omecamtiv mecarbil might be less effective in patients with atrial fibrillation or flutter
Vericiguat effective irrespective of atrial fibrillation status
Baroreflex activation: a novel option to improve heart failure symptoms
Beta-blocker withdrawal to enhance exercise capacity in heart failure?
Inconclusive results for dapagliflozin treatment in heart failure
Computerised cognitive training improves cognitive function in HF patients
Real-world study suggests sacubitril/valsartan benefits elderly patients with HF
Proenkephalin: A useful biomarker for new-onset heart failure?
Weight loss associated with increased mortality risk in heart failure patients
Echocardiographic parameters linked to dementia diagnosis
Telemedicine: Every light has its shadow
COVID-19-related HF: from systemic infection to cardiac inflammation
Increased COVID-19 mortality in patients with cardiorenal comorbidity
Myocardial infarction outcomes were significantly affected by the pandemic
Empagliflozin linked to lower cardiovascular risk and renal events in real-world study
Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status
TAPSE effective biomarker associated with high-risk of severe COVID-19
COVID-19 in AF patients with HF: no higher mortality but longer hospital stay
Biomarker panel predicts SGLT2 inhibitor response
Psychoactive substances put young people at risk of cardiovascular disease
Heart failure patients might be at an increased risk for head and neck cancer
The challenge of improving the quality of life of heart failure patients
Progressive rehabilitation improves outcomes for elderly heart failure patients
PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events
Older adults with heart failure benefit from rehabilitation programme
Quality improvement intervention fails to improve care for patients with heart failure
Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF
Ablation-based rhythm control as effective as rate control in AF and HF
Sotagliflozin reduces disease burden in diabetes with worsening heart failure
RACE 3 long-term results show fading benefit of targeted therapies in AF and HF
Pericardial fat tied to increased heart failure risk, particularly for women
Cardiac-myosin activator yields greatest benefit in severe heart failure
Aggressive rehabilitation helps frail heart-failure patients
Dapagliflozin benefits in type-2 diabetes consistent across kidney-function groups
KCCQ-OS more likely than NYHA class to detect health status changes in heart failure
Diuretic effect may not mediate most empagliflozin benefits in heart-failure patients
Omecamtiv mecarbil improves outcomes in HFrEF-patients
IV iron reduces HF hospitalisation
Dapagliflozin reduces renal risk independent of CV disease status
“Strongly consider an SGLT2-inhibitor in most T2DM patients”
Additional HFrEF education and patient-engagement tools
Could statins protect the heart from breast-cancer chemotherapy?
TTR V122I variant linked to adverse cardiac mechanics in middle-aged Black Americans
Study links fracking operations to worsening heart failure
Sedentary time tied to heart failure hospitalization in postmenopausal women
SGLT2 inhibitor reduces filling pressure in HFrEF patients
Studies show cardiovascular benefit with sotagliflozin
Correcting iron deficiency protects heart failure patients from repeat hospital stay
Amgen drug shaves 8% off risk of heart-failure event or heart death
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
Reduced NT-proBNP in HFpEF with sacubitril/valsartan
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
Serum omega-3 fatty acids tied to improved STEMI prognosis
Ertugliflozin passes post-approval cardiovascular safety test
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
ISCHEMIA trial: Invasive treatment only better for angina burden
Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications
BNP still a reliable prognostic marker before and during sacubitril/valsartan treatment
High 5-year survival rates for older HF patients without initial severe comorbidity
